Via: OncoMed
NEW YORK and REDWOOD CITY, Calif., Sept. 16, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today presented preclinical data for the company's proprietary, wholly owned GITRL-Fc agent during the afternoon poster session of the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference.
GITRL is a member of the tumor necrosis factor (TNF) family of ligands and functions to activate the co-stimulatory receptor GITR (glucocorticoid-induced tumor necrosis factor receptors) to enhance T-cell modulated immune responses. OncoMed's GITRL-Fc agent is engineered using a novel single-gene linkerless GITRL trimer which enables effective GITR activation and robust anti-tumor immune response.
"The single-gene linkerless trimer technology we have created provides a flexible platform for the design of additional immuno-oncology agents, including bispecific agents," said Austin Gurney, PhD, Senior Vice President of Molecular and Cellular Biology. "We observed improved activation of GITR and highly potent single-agent activity using our GITRL fusion protein, and also noted that GITRL-Fc shows strong additivity with other immune checkpoint blockers. These data demonstrate a powerful new class of immunotherapeutic agent."
Read More: http://investor.shareholder.com/oncomed/releasedetail.cfm?ReleaseID=931976
RSS Feed
